Drug
Glecirasib clinical trials
Also written JAB-21822.
- studies test it
- 13
- open now
- 7
- in phase 3
- 1
- first study started
- 2021
Keep track of what changes. Save the glecirasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 8
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 3
Allist Pharmaceuticals, Inc. (9) · Jian Li (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Sitneprotafib (2) · Cetuximab (1) · Bevacizumab (1) · Izalontamab brengitecan (1) · Ivonescimab (1) · Sunvozertinib (1) · Crizotinib (1) · Pralsetinib (1)
Studies
Open first, then newest update. How each study uses glecirasib is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07827261Written as Glecirasib
- A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1RecruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05276726Written as JAB 21822
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06416410Written as JAB-21822
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05288205Written as JAB-21822
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Glecirasib
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingPhase 2Allist Pharmaceuticals, Inc.NCT06008288Written as JAB-21822
- Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07339839Written as Glecirasib
- A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive, not recruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05009329Written as JAB-21822
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05194995Written as JAB-21822
- JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRCActive, not recruitingPhase 1Jian LiNCT06838338Written as JAB-21822
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy SubjectsCompletedPhase 1Allist Pharmaceuticals, Inc.NCT06162169Written as JAB-21822
- Mass Balance Study of [14C]JAB-21822CompletedPhase 1Allist Pharmaceuticals, Inc.NCT05920941Written as [14C]JAB-21822
- A Food Effect Study of JAB-21822 in Healthy SubjectsCompletedPhase 1Allist Pharmaceuticals, Inc.NCT05875493Written as JAB-21822
Given in every arm · 1 — glecirasib is usual care beside what is tested
Codes
What other systems call glecirasib · ClinicalTrials.gg INT018156
- UNII (FDA) UP75WH4QKMGLECIRASIBOne source FDA
- NCI Thesaurus C181904GlecirasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UP75WH4QKM | GLECIRASIB | One source FDA |
| NCI Thesaurus | C181904 | Glecirasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.